Scott D. Wrigley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott D. Wrigley has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Tiffany L. Weir
Intestinal Health Lab, Department of Food Science and Human Nutrition, Colorado State University, United States
7 shared publications - Christopher L. Gentile
Department of Food Science and Human Nutrition, College of Health and Human Sciences, Colorado State University , Fort Collins, USA
4 shared publications Dustin M. Lee
Brooke Army Medical Center
4 shared publicationsKayl E. Ecton
Colorado State University
4 shared publicationsKeely N. Thomas
Colorado State University
4 shared publicationsMicah L. Battson
Metropolitan State University
4 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
A human microbiota-associated translational mouse model reveals sex-specific responses to cannabidiol and cannabigerol
Cannabidiol (CBD) and cannabigerol (CBG) are non-psychoactive phytocannabinoids with therapeutic potential, yet their effects on host physiology and interactions with the gut microbiome remain poorly defined. Here, we used a translational mouse model colonized with human-associated microbiotas to investigate the effects of oral CBD and CBG intervention on microbial composition, endocannabinoid signaling, and intestinal protein expression. While neither phytocannabinoids altered overall gut microbiome diversity, both induced sex-specific shifts in bacterial taxa associated with mucin utilization and short-chain fatty acid production. Circulating concentrations of CBD were higher than those of CBG, and females exhibited higher plasma phytocannabinoid concentrations than males. Males treated with CBD had elevated anandamide (AEA) levels, potentially reflecting inhibition of fatty acid amide hydrolase, consistent with upregulation of serine protease inhibitors observed in ileal proteomes. Females also accumulated more subcutaneous adipose tissue with both CBD and CBG treatment resulting in greater total CBD storage in this depot. Collectively, these findings suggest sex-specific interactions between phytocannabinoids, the endocannabinoid system, and the gut microbiome, underscoring the importance of considering biological sex in cannabinoid research and informing personalized therapeutic strategies.
- 13 August 2026
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 8 (1)
Open AccessA human microbiota-associated translational mouse model reveals sex-specific responses to cannabidiol and cannabigerol
Cannabidiol (CBD) and cannabigerol (CBG) are non-psychoactive phytocannabinoids with therapeutic potential, yet their effects on host physiology and interactions with the gut microbiome remain poorly defined. Here, we used a translational mouse model colonized with human-associated microbiotas to investigate the effects of oral CBD and CBG intervention on microbial composition, endocannabinoid signaling, and intestinal protein expression. While neither phytocannabinoids altered overall gut microbiome diversity, both induced sex-specific shifts in bacterial taxa associated with mucin utilization and short-chain fatty acid production. Circulating concentrations of CBD were higher than those of CBG, and females exhibited higher plasma phytocannabinoid concentrations than males. Males treated with CBD had elevated anandamide (AEA) levels, potentially reflecting inhibition of fatty acid amide hydrolase, consistent with upregulation of serine protease inhibitors observed in ileal proteomes. Females also accumulated more subcutaneous adipose tissue with both CBD and CBG treatment resulting in greater total CBD storage in this depot. Collectively, these findings suggest sex-specific interactions between phytocannabinoids, the endocannabinoid system, and the gut microbiome, underscoring the importance of considering biological sex in cannabinoid research and informing personalized therapeutic strategies.
- Open Access
Effects of Supplementation with Microalgae Extract from Tetradesmus obliquus Strain Mi175.B1.a on Gastrointestinal Symptoms and Mental Health in Healthy Adults: A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Trial
Microalgae, a marine-derived natural ingredient, has emerged as a rich source of bioactive compounds with the potential to modulate gut–brain axis activities. The objective of this study was to investigate whether supplementation with a microalgae extract from Tetradesmus obliquus strain Mi175.B1.a (TOME) influences gut health and reduces stress and anxiety in healthy adults experiencing mild to moderate gastrointestinal (GI) distress. Methods: Fifty-six healthy adults (age: 31.9 ± 7.7 years; body weight: 71.8 ± 12.6 kg; BMI: 24.6 ± 2.8 kg/m2) were enrolled in a randomized, double-blind, placebo-controlled, parallel-arm clinical trial. Participants were randomly allocated to receive capsules containing either 250 mg/day of TOME or a placebo for four weeks. Primary outcomes included the assessment of GI symptoms using the Gastrointestinal Symptom Rating Scale (GSRS) and Bristol Stool Scale (BSS). Secondary outcomes focused on subjective evaluation of mood, stress, and anxiety, as well as blood pressure responses to sympathetic nervous system activation induced by the cold pressor test (CPT). In addition, stool, plasma, and saliva samples were collected to assess biomarkers associated with stress, sympathetic activation, intestinal permeability, and GI health. 16S rRNA sequencing was performed to analyze changes in gut microbial populations. Results: Daily supplementation for four weeks with TOME was safe and well tolerated in the study population. In addition, TOME significantly reduced GSRS global scores (p = 0.02), as well as constipation (p = 0.05) and indigestion (p = 0.03) subcomponent scores compared to Placebo. There was also a significant increase in Shannon’s index before FDR correction (p = 0.05; FDR = 0.12) and stool butyrate level was significantly lower in the TOME group than in Placebo after 4 weeks of supplementation (p = 0.039). Both groups showed a significant reduction in perceived stress scores, but the TOME intervention group also had reduced Negative Affect scores (p < 0.001). In addition, plasma chromogranin A, a stress biomarker, was significantly reduced after TOME intervention (p = 0.03). There were no negative effects on blood lipids or other parameters related to sympathetic activation or cardiovascular health. Conclusions: Overall, these results suggest that 4-week supplementation with T. obliquus strain Mi175.B1.a improves GI symptoms, potentially through effects on the gut microbiota, and may promote positive effects on mental health. Additional research should follow up on mental health outcomes in populations with increased stress and anxiety and investigate mechanisms underlying improvements in GI health. This trial was registered at clinicaltrials.gov as NCT06425094.
Open AccessEffects of Supplementation with Microalgae Extract from Tetradesmus obliquus Strain Mi175.B1.a on Gastrointestinal Symptoms and Mental Health in Healthy Adults: A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Trial
Microalgae, a marine-derived natural ingredient, has emerged as a rich source of bioactive compounds with the potential to modulate gut–brain axis activities. The objective of this study was to investigate whether supplementation with a microalgae extract from Tetradesmus obliquus strain Mi175.B1.a (TOME) influences gut health and reduces stress and anxiety in healthy adults experiencing mild to moderate gastrointestinal (GI) distress. Methods: Fifty-six healthy adults (age: 31.9 ± 7.7 years; body weight: 71.8 ± 12.6 kg; BMI: 24.6 ± 2.8 kg/m2) were enrolled in a randomized, double-blind, placebo-controlled, parallel-arm clinical trial. Participants were randomly allocated to receive capsules containing either 250 mg/day of TOME or a placebo for four weeks. Primary outcomes included the assessment of GI symptoms using the Gastrointestinal Symptom Rating Scale (GSRS) and Bristol Stool Scale (BSS). Secondary outcomes focused on subjective evaluation of mood, stress, and anxiety, as well as blood pressure responses to sympathetic nervous system activation induced by the cold pressor test (CPT). In addition, stool, plasma, and saliva samples were collected to assess biomarkers associated with stress, sympathetic activation, intestinal permeability, and GI health. 16S rRNA sequencing was performed to analyze changes in gut microbial populations. Results: Daily supplementation for four weeks with TOME was safe and well tolerated in the study population. In addition, TOME significantly reduced GSRS global scores (p = 0.02), as well as constipation (p = 0.05) and indigestion (p = 0.03) subcomponent scores compared to Placebo. There was also a significant increase in Shannon’s index before FDR correction (p = 0.05; FDR = 0.12) and stool butyrate level was significantly lower in the TOME group than in Placebo after 4 weeks of supplementation (p = 0.039). Both groups showed a significant reduction in perceived stress scores, but the TOME intervention group also had reduced Negative Affect scores (p < 0.001). In addition, plasma chromogranin A, a stress biomarker, was significantly reduced after TOME intervention (p = 0.03). There were no negative effects on blood lipids or other parameters related to sympathetic activation or cardiovascular health. Conclusions: Overall, these results suggest that 4-week supplementation with T. obliquus strain Mi175.B1.a improves GI symptoms, potentially through effects on the gut microbiota, and may promote positive effects on mental health. Additional research should follow up on mental health outcomes in populations with increased stress and anxiety and investigate mechanisms underlying improvements in GI health. This trial was registered at clinicaltrials.gov as NCT06425094.
- Open Access
Short-Term Magnesium Supplementation Has Modest Detrimental Effects on Cycle Ergometer Exercise Performance and Skeletal Muscle Mitochondria and Negligible Effects on the Gut Microbiota: A Randomized Crossover Clinical Trial
Background/Objectives: Although the importance of magnesium for overall health and physiological function is well established, its influence on exercise performance is less clear. The primary study objective was to determine the influence of short-term magnesium supplementation on cycle ergometer exercise performance. The hypothesis was that magnesium would elicit an ergogenic effect. Methods: A randomized, double-blind, placebo-controlled, two-period crossover design was used to study men and women who were regular exercisers. Fifteen participants ingested either a placebo or magnesium chloride (MgCl2 300 mg) twice per day, for 9 days, separated by a 3-week washout. During days 8 and 9, participants completed a battery of cycle ergometer exercise tests, and whole blood, vastus lateralis, and stools were sampled. The primary outcomes were the maximal oxygen uptake (VO2max), a simulated 10 km time trial, and the sprint exercise performance. Additional outcomes included skeletal muscle mitochondrial respiration, and, on account of the known laxative effects of magnesium, the gut microbiota diversity. Results: Compared with a placebo, MgCl2 supplementation increased the circulating ionized Mg concentration (p < 0.03), decreased the VO2max (44.4 ± 7.7 vs. 41.3 ± 8.0 mL/kg/min; p = 0.005), and decreased the mean power output during a 30 s sprint (439 ± 88 vs. 415 ± 88 W; p = 0.03). The 10 km time trial was unaffected (1282 ± 126 vs. 1281 ± 97 s; p = 0.89). In skeletal muscle, MgCl2 decreased mitochondrial respiration in the presence of fatty acids at complex II (p = 0.04). There were no significant impacts on the gut microbiota richness (CHAO1; p = 0.68), Shannon’s Diversity (p = 0.23), or the beta-diversity (Bray–Curtis distances; p = 0.74). Conclusions: In summary, magnesium supplementation had modest ergolytic effects on cycle ergometer exercise performance and mitochondrial respiration. We recommend that regular exercisers, free from hypomagnesemia, should not supplement their diet with magnesium.
Open AccessShort-Term Magnesium Supplementation Has Modest Detrimental Effects on Cycle Ergometer Exercise Performance and Skeletal Muscle Mitochondria and Negligible Effects on the Gut Microbiota: A Randomized Crossover Clinical Trial
Background/Objectives: Although the importance of magnesium for overall health and physiological function is well established, its influence on exercise performance is less clear. The primary study objective was to determine the influence of short-term magnesium supplementation on cycle ergometer exercise performance. The hypothesis was that magnesium would elicit an ergogenic effect. Methods: A randomized, double-blind, placebo-controlled, two-period crossover design was used to study men and women who were regular exercisers. Fifteen participants ingested either a placebo or magnesium chloride (MgCl2 300 mg) twice per day, for 9 days, separated by a 3-week washout. During days 8 and 9, participants completed a battery of cycle ergometer exercise tests, and whole blood, vastus lateralis, and stools were sampled. The primary outcomes were the maximal oxygen uptake (VO2max), a simulated 10 km time trial, and the sprint exercise performance. Additional outcomes included skeletal muscle mitochondrial respiration, and, on account of the known laxative effects of magnesium, the gut microbiota diversity. Results: Compared with a placebo, MgCl2 supplementation increased the circulating ionized Mg concentration (p < 0.03), decreased the VO2max (44.4 ± 7.7 vs. 41.3 ± 8.0 mL/kg/min; p = 0.005), and decreased the mean power output during a 30 s sprint (439 ± 88 vs. 415 ± 88 W; p = 0.03). The 10 km time trial was unaffected (1282 ± 126 vs. 1281 ± 97 s; p = 0.89). In skeletal muscle, MgCl2 decreased mitochondrial respiration in the presence of fatty acids at complex II (p = 0.04). There were no significant impacts on the gut microbiota richness (CHAO1; p = 0.68), Shannon’s Diversity (p = 0.23), or the beta-diversity (Bray–Curtis distances; p = 0.74). Conclusions: In summary, magnesium supplementation had modest ergolytic effects on cycle ergometer exercise performance and mitochondrial respiration. We recommend that regular exercisers, free from hypomagnesemia, should not supplement their diet with magnesium.
- Open Access
- 28 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2453
Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111
Probiotics make up a large and growing segment of the commercial market of dietary supplements and are touted as offering a variety of human health benefits. Some of the purported positive impacts of probiotics include, but are not limited to, stabilization of the gut microbiota, prevention of gastrointestinal disorders and modulation of the host immune system. Current research suggests that the immunomodulatory effects of probiotics are strain-specific and vary in mode of action. Here, we examined the immunomodulatory properties of Bacillus subtilis strain DE111 in a healthy human population. In a pilot randomized, double blind, placebo-controlled four-week intervention, we examined peripheral blood mononuclear cells (PBMCs) at basal levels pre- and post-intervention, as well as in response to stimulation with bacterial lipopolysaccharide (LPS). We observed an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs in the DE111 intervention group. Overall perceived gastrointestinal health, microbiota, and circulating and fecal markers of inflammation (Il-6, sIgA) and gut barrier function (plasma zonulin) were largely unaffected by DE111 intervention, although the study may have been underpowered to detect these differences. These pilot data provide information and justification to conduct an appropriately powered clinical study to further examine the immunomodulatory potential of B. subtilis DE111 in human populations.
- 28 February 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2453
Open AccessExamining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111
Probiotics make up a large and growing segment of the commercial market of dietary supplements and are touted as offering a variety of human health benefits. Some of the purported positive impacts of probiotics include, but are not limited to, stabilization of the gut microbiota, prevention of gastrointestinal disorders and modulation of the host immune system. Current research suggests that the immunomodulatory effects of probiotics are strain-specific and vary in mode of action. Here, we examined the immunomodulatory properties of Bacillus subtilis strain DE111 in a healthy human population. In a pilot randomized, double blind, placebo-controlled four-week intervention, we examined peripheral blood mononuclear cells (PBMCs) at basal levels pre- and post-intervention, as well as in response to stimulation with bacterial lipopolysaccharide (LPS). We observed an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs in the DE111 intervention group. Overall perceived gastrointestinal health, microbiota, and circulating and fecal markers of inflammation (Il-6, sIgA) and gut barrier function (plasma zonulin) were largely unaffected by DE111 intervention, although the study may have been underpowered to detect these differences. These pilot data provide information and justification to conduct an appropriately powered clinical study to further examine the immunomodulatory potential of B. subtilis DE111 in human populations.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Gut Microbes
- Vol. 13 (1) , 1940791
Transplantation of an obesity-associated human gut microbiota to mice induces vascular dysfunction and glucose intolerance
Recent preclinical data suggest that alterations in the gut microbiota may be an important factor linking obesity to vascular dysfunction, an early sign of cardiovascular disease. The purpose of this study was to begin translation of these preclinical data by examining whether vascular phenotypes in humans are transmissible through the gut microbiota. We hypothesized that germ-free mice colonized with gut microbiota from obese individuals would display diminished vascular function compared to germ-free mice receiving microbiota from lean individuals. We transplanted fecal material from obese and lean age-and sex-matched participants with disparate vascular function to germ-free mice. Using Principle Component Analysis, the microbiota of colonized mice separated by donor group along the first principle component, accounting for between 70–93% of the total variability in the dataset. The microbiota of mice receiving transplants from lean individuals was also characterized by increased alpha diversity, as well as increased relative abundance of potentially beneficial bacteria, including Bifidobacterium, Lactobacillus, and Bacteroides ovatis. Endothelium-dependent dilation, aortic pulse wave velocity and glucose tolerance were significantly altered in mice receiving microbiota from the obese donor relative to those receiving microbiota from the lean donor or those remaining germ-free. These data indicate that the obesity-associated human gut microbiota is sufficient to alter the vascular phenotype in germ-free mice in the absence of differences in body weight or dietary manipulation, and provide justification for future clinical trials to test the efficacy of microbiota-targeted therapies in the prevention or treatment of cardiovascular disease.
- 1 January 2021
- Published by Taylor & Francis in Gut Microbes
- Vol. 13 (1) , 1940791
Open AccessTransplantation of an obesity-associated human gut microbiota to mice induces vascular dysfunction and glucose intolerance
Recent preclinical data suggest that alterations in the gut microbiota may be an important factor linking obesity to vascular dysfunction, an early sign of cardiovascular disease. The purpose of this study was to begin translation of these preclinical data by examining whether vascular phenotypes in humans are transmissible through the gut microbiota. We hypothesized that germ-free mice colonized with gut microbiota from obese individuals would display diminished vascular function compared to germ-free mice receiving microbiota from lean individuals. We transplanted fecal material from obese and lean age-and sex-matched participants with disparate vascular function to germ-free mice. Using Principle Component Analysis, the microbiota of colonized mice separated by donor group along the first principle component, accounting for between 70–93% of the total variability in the dataset. The microbiota of mice receiving transplants from lean individuals was also characterized by increased alpha diversity, as well as increased relative abundance of potentially beneficial bacteria, including Bifidobacterium, Lactobacillus, and Bacteroides ovatis. Endothelium-dependent dilation, aortic pulse wave velocity and glucose tolerance were significantly altered in mice receiving microbiota from the obese donor relative to those receiving microbiota from the lean donor or those remaining germ-free. These data indicate that the obesity-associated human gut microbiota is sufficient to alter the vascular phenotype in germ-free mice in the absence of differences in body weight or dietary manipulation, and provide justification for future clinical trials to test the efficacy of microbiota-targeted therapies in the prevention or treatment of cardiovascular disease.
- 1 January 2021
- Published by Elsevier
- p. 532-541
Nutritional Regulation of the Microbiota - Can One Meal Change a Trillion Lives?
- 1 January 2021
- Published by Elsevier
- p. 532-541
Nutritional Regulation of the Microbiota - Can One Meal Change a Trillion Lives?
- Open Access
PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults
Probiotics are increasingly used by consumers and practitioners to reduce gastrointestinal (GI) distress and improve gut function. Here, we sought to determine whether the addition of supplemental bacteriophages (PreforPro) could enhance the effects of a common probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) on GI health. A total of 68 participants were enrolled in a 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial where primary outcomes included self-assessments of GI health, a daily stool log, and 16s rRNA analysis of gut microbial populations. We observed within-group improvements in GI inflammation (p = 0.01) and a trending improvement in colon pain (p = 0.08) in individuals consuming B. lactis with PreforPro, but not in the group consuming only the probiotic. There was also a larger increase in Lactobacillus and short-chain fatty acid-producing microbial taxa detected in the stool of participants taking PreforPro with B. lactis compared to the probiotic alone. Overall, these results suggest the addition of PreforPro as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics.
Open AccessPHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults
Probiotics are increasingly used by consumers and practitioners to reduce gastrointestinal (GI) distress and improve gut function. Here, we sought to determine whether the addition of supplemental bacteriophages (PreforPro) could enhance the effects of a common probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) on GI health. A total of 68 participants were enrolled in a 4-week, randomized, parallel-arm, double-blind, placebo-controlled trial where primary outcomes included self-assessments of GI health, a daily stool log, and 16s rRNA analysis of gut microbial populations. We observed within-group improvements in GI inflammation (p = 0.01) and a trending improvement in colon pain (p = 0.08) in individuals consuming B. lactis with PreforPro, but not in the group consuming only the probiotic. There was also a larger increase in Lactobacillus and short-chain fatty acid-producing microbial taxa detected in the stool of participants taking PreforPro with B. lactis compared to the probiotic alone. Overall, these results suggest the addition of PreforPro as a combination therapy may alter gut ecology to extend the GI benefits of consuming B. lactis or other probiotics.
- Open Access
- 29 May 2020
- Published by Elsevier in Current Developments in Nutrition
- Vol. 4 (Supplement) , 428
Effects of Red Beetroot Juice and Inorganic Nitrate Supplementation on Oral Bacteria and Nitric Oxide Metabolites in Middle-Aged/Older Adults with Overweight and Obesity
Dietary inorganic nitrate from foods such as red beetroot juice (RBJ) can contribute to nitric oxide (NO) bioavailability through the enterosalivary nitrate-nitrite-NO pathway. A critical step in this pathway is the reduction of nitrate to nitrite by oral bacteria. We investigated the effects of inorganic nitrate supplementation, as RBJ or placebo + potassium nitrate (PBO+NIT), on the oral microbiota, and its relationship with saliva and plasma NO metabolites and vascular endothelial function. In a randomized, double-blind, placebo-controlled trial, we measured the abundance of oral nitrate-reducing bacteria in saliva samples from 15 middle-aged/older adults with overweight and obesity using 16 rRNA sequencing. We also assessed the relationship of oral nitrate-reducing bacteria with the physiological responses to acute (4 hours) and chronic (4 weeks) RBJ, PBO+NIT, nitrate-free RBJ, and placebo supplementation via measurement of saliva and plasma nitrate/nitrite (NOx), plasma nitrite levels, and reactive hyperemia index (RHI). A significant decrease in the alpha diversity metric, Pileou's Evenness, was detected after chronic consumption of PBO+NIT (0.69 ± 0.05 at week 0 vs. 0.65 ± 0.05 at week 4; P < 0.05), while there was a trend for a decline following RBJ consumption (0.69 ± 0.05 at week 0 vs. 0.65 ± 0.05 at week 4; P = 0.08). No significant differences in abundance of nitrate-reducing bacteria were observed after chronic supplementation, although abundance of the species Neisseria subflava was trending toward an increase in the RBJ group (10.8% at week 0 vs. 12.2% at week 4; P = 0.07). Plasma and saliva NOx increased from baseline and remained elevated for the 4-hour testing period after acute and chronic RBJ and PBO+NIT supplementation (all P < 0.05), while plasma nitrite only peaked at 2 hours in the RBJ group after acute supplementation and was significantly higher than PBO+NIT group (P < 0.01). RHI change from baseline to 4 hours was positively correlated with total abundance of nitrate-reducing species after chronic RBJ supplementation (r = 0.5; P = 0.05). Acute and chronic RBJ and PBO+NIT supplementation increases NO metabolites and may alter the oral microbiota to favorably affect vascular endothelial function in middle-aged/older adults with overweight and obesity. NIFA, USDA.
- 29 May 2020
- Published by Elsevier in Current Developments in Nutrition
- Vol. 4 (Supplement) , 428
Open AccessEffects of Red Beetroot Juice and Inorganic Nitrate Supplementation on Oral Bacteria and Nitric Oxide Metabolites in Middle-Aged/Older Adults with Overweight and Obesity
Dietary inorganic nitrate from foods such as red beetroot juice (RBJ) can contribute to nitric oxide (NO) bioavailability through the enterosalivary nitrate-nitrite-NO pathway. A critical step in this pathway is the reduction of nitrate to nitrite by oral bacteria. We investigated the effects of inorganic nitrate supplementation, as RBJ or placebo + potassium nitrate (PBO+NIT), on the oral microbiota, and its relationship with saliva and plasma NO metabolites and vascular endothelial function. In a randomized, double-blind, placebo-controlled trial, we measured the abundance of oral nitrate-reducing bacteria in saliva samples from 15 middle-aged/older adults with overweight and obesity using 16 rRNA sequencing. We also assessed the relationship of oral nitrate-reducing bacteria with the physiological responses to acute (4 hours) and chronic (4 weeks) RBJ, PBO+NIT, nitrate-free RBJ, and placebo supplementation via measurement of saliva and plasma nitrate/nitrite (NOx), plasma nitrite levels, and reactive hyperemia index (RHI). A significant decrease in the alpha diversity metric, Pileou's Evenness, was detected after chronic consumption of PBO+NIT (0.69 ± 0.05 at week 0 vs. 0.65 ± 0.05 at week 4; P < 0.05), while there was a trend for a decline following RBJ consumption (0.69 ± 0.05 at week 0 vs. 0.65 ± 0.05 at week 4; P = 0.08). No significant differences in abundance of nitrate-reducing bacteria were observed after chronic supplementation, although abundance of the species Neisseria subflava was trending toward an increase in the RBJ group (10.8% at week 0 vs. 12.2% at week 4; P = 0.07). Plasma and saliva NOx increased from baseline and remained elevated for the 4-hour testing period after acute and chronic RBJ and PBO+NIT supplementation (all P < 0.05), while plasma nitrite only peaked at 2 hours in the RBJ group after acute supplementation and was significantly higher than PBO+NIT group (P < 0.01). RHI change from baseline to 4 hours was positively correlated with total abundance of nitrate-reducing species after chronic RBJ supplementation (r = 0.5; P = 0.05). Acute and chronic RBJ and PBO+NIT supplementation increases NO metabolites and may alter the oral microbiota to favorably affect vascular endothelial function in middle-aged/older adults with overweight and obesity. NIFA, USDA.
- 18 May 2020
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 319 (1) , G51-G62
Microbial metabolite indole-3-propionic acid supplementation does not protect mice from the cardiometabolic consequences of a Western diet
The gut microbiota has been shown to mediate host health. Emerging data implicate gut microbial metabolites of tryptophan metabolism as potential important mediators. We examined the effects of indole-3-propionic acid in Western diet-fed mice and found no beneficial cardiometabolic effects. Our data do not support the supposition that indole-3-propionic acid (IPA) mediates beneficial metabolic effects downstream of the gut microbiota and may be potentially deleterious in higher circulating levels.
- 18 May 2020
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 319 (1) , G51-G62
Microbial metabolite indole-3-propionic acid supplementation does not protect mice from the cardiometabolic consequences of a Western diet
The gut microbiota has been shown to mediate host health. Emerging data implicate gut microbial metabolites of tryptophan metabolism as potential important mediators. We examined the effects of indole-3-propionic acid in Western diet-fed mice and found no beneficial cardiometabolic effects. Our data do not support the supposition that indole-3-propionic acid (IPA) mediates beneficial metabolic effects downstream of the gut microbiota and may be potentially deleterious in higher circulating levels.
- Open Access
- 18 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Identifying Candidates for Novel Customized Probiotics Targeting Obesity‐Related Vascular Dysfunction
Objectives: The gut microbiota has emerged as a critical regulator of human health. Consequently, commercial probiotics have grown in popularity and become a multi‐billion dollar industry. However, existing data have questioned the efficacy of commercial probiotics in the treatment and prevention of chronic diseases. One possible reason for the limited efficacy is that commercial probiotics are formulated indiscriminately, without regard to the gut microbial deficiencies of the patients. A more effective approach may be to administer the specific bacterial species that are reduced in the patient population, and whose reduction correlates with the presence of disease. Therefore, the goal of this project was to identify potential bacterial species for the formulation of a novel customized probiotic for the treatment and prevention of obesity‐related vascular dysfunction. Methods: In order to identify potential candidates for a customized probiotic, data were pooled from the following mice in five independent studies that examined the role of the gut microbiota in obesity‐related vascular dysfunction: 1) C57BL/6 male mice fed either a standard low‐fat or Western diet; 2) lean male C57BL/6 mice that received microbiota transplantation from other C57BL/6 mice or from genetically obese ( ob/ob ) mice; 3) male ob/ob mice that received microbiota transplantation from other ob/ob mice or from lean C57BL/6 mice; 4) male genetically obese, diabetic ( db/db ) mice; and 5) male and female germ free mice that received microbiota transplantation from either lean or obese human donors. All mice underwent measurement of microbiota composition, arterial stiffness (via pulse wave velocity), endothelial function (via endothelium‐dependent dilation of mesenteric arteries) and glucose tolerance (via ip glucose tolerance test), and relations between these outcomes and individual bacterial species were examined. Results: In the pooled cohort, we found that the abundance of Akkermansia (p = 0.09) and Bifidobacterium (p = 0.015) were significantly reduced in obese mice (or mice treated with obese microbiota) compared to lean mice. Pulse wave velocity and glucose tolerance negatively correlated with both Akkermansia (r = − 0.438, p Bifidobacterium (r = − 0.171, p = 0.170; r = − 0.207, p = 0.1068), respectively. Body weight negatively correlated with Bifidobacterium (r = −0.607, p < 0.0001). Both endothelial dependent dilation (r = 0.317, p = 0.0236), and endothelial independent dilation (r = 0.222, p = 0.129) positively correlated with Bifidobacterium but not with Akkermansia. Conclusions: These data indicate that genetically‐ and diet‐induced obese mice display relative deficiencies of Akkermansia and Bifidobacterium which correlate with measures of metabolic and vascular dysfunction, suggesting that these bacterial species are potential candidates for a customized probiotic. Future studies will compare the efficacy of a commercial probiotic to a customized probiotic, specifically formulated to ameliorate these bacterial deficiencies, in preventing or reversing obesity‐related vascular dysfunction. Support or Funding Information: NIH R01 HL14411; American Heart Association #18TPA34170585; NIFA AES COL00766
- 18 April 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (S1) , 1
Open AccessIdentifying Candidates for Novel Customized Probiotics Targeting Obesity‐Related Vascular Dysfunction
Objectives: The gut microbiota has emerged as a critical regulator of human health. Consequently, commercial probiotics have grown in popularity and become a multi‐billion dollar industry. However, existing data have questioned the efficacy of commercial probiotics in the treatment and prevention of chronic diseases. One possible reason for the limited efficacy is that commercial probiotics are formulated indiscriminately, without regard to the gut microbial deficiencies of the patients. A more effective approach may be to administer the specific bacterial species that are reduced in the patient population, and whose reduction correlates with the presence of disease. Therefore, the goal of this project was to identify potential bacterial species for the formulation of a novel customized probiotic for the treatment and prevention of obesity‐related vascular dysfunction. Methods: In order to identify potential candidates for a customized probiotic, data were pooled from the following mice in five independent studies that examined the role of the gut microbiota in obesity‐related vascular dysfunction: 1) C57BL/6 male mice fed either a standard low‐fat or Western diet; 2) lean male C57BL/6 mice that received microbiota transplantation from other C57BL/6 mice or from genetically obese ( ob/ob ) mice; 3) male ob/ob mice that received microbiota transplantation from other ob/ob mice or from lean C57BL/6 mice; 4) male genetically obese, diabetic ( db/db ) mice; and 5) male and female germ free mice that received microbiota transplantation from either lean or obese human donors. All mice underwent measurement of microbiota composition, arterial stiffness (via pulse wave velocity), endothelial function (via endothelium‐dependent dilation of mesenteric arteries) and glucose tolerance (via ip glucose tolerance test), and relations between these outcomes and individual bacterial species were examined. Results: In the pooled cohort, we found that the abundance of Akkermansia (p = 0.09) and Bifidobacterium (p = 0.015) were significantly reduced in obese mice (or mice treated with obese microbiota) compared to lean mice. Pulse wave velocity and glucose tolerance negatively correlated with both Akkermansia (r = − 0.438, p Bifidobacterium (r = − 0.171, p = 0.170; r = − 0.207, p = 0.1068), respectively. Body weight negatively correlated with Bifidobacterium (r = −0.607, p < 0.0001). Both endothelial dependent dilation (r = 0.317, p = 0.0236), and endothelial independent dilation (r = 0.222, p = 0.129) positively correlated with Bifidobacterium but not with Akkermansia. Conclusions: These data indicate that genetically‐ and diet‐induced obese mice display relative deficiencies of Akkermansia and Bifidobacterium which correlate with measures of metabolic and vascular dysfunction, suggesting that these bacterial species are potential candidates for a customized probiotic. Future studies will compare the efficacy of a commercial probiotic to a customized probiotic, specifically formulated to ameliorate these bacterial deficiencies, in preventing or reversing obesity‐related vascular dysfunction. Support or Funding Information: NIH R01 HL14411; American Heart Association #18TPA34170585; NIFA AES COL00766